Amgen (AMGN) Research & Development (2009 - 2026)

Amgen has reported Research & Development for 18 years, with the latest figure at $1.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 15.68% year-over-year to $1.7 billion; the trailing twelve-month figure through Mar 2026 stood at $7.5 billion (up 22.89% YoY), and the FY2025 full-year result was $7.3 billion, up 21.93% from the prior year.
• Research & Development for Q1 2026 stood at $1.7 billion, down from $2.1 billion in the prior quarter.
• The five-year high for Research & Development was $2.1 billion in Q4 2025, with the low at $959.0 million in Q1 2022.
• Average Research & Development over 5 years is $1.4 billion, with a median of $1.4 billion recorded in 2024.
• Year-over-year, Research & Development dropped 21.8% in 2022 and jumped 34.38% in 2024.
• Tracing AMGN's Research & Development over 5 years: stood at $1.3 billion in 2022, then grew by 15.86% to $1.5 billion in 2023, then grew by 12.39% to $1.7 billion in 2024, then rose by 24.25% to $2.1 billion in 2025, then dropped by 19.75% to $1.7 billion in 2026.
• The last three Research & Development figures came in at $1.7 billion (Q1 2026), $2.1 billion (Q4 2025), and $1.9 billion (Q3 2025), per Business Quant data.

Peer Comparison